ALIM:NSD-Alimera Sciences, Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 7.66

Change

-0.54 (-6.59)%

Market Cap

USD 0.05B

Volume

0.05M

Average Target Price

USD 15.00 (+95.82%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. The company sells its products through direct sales and distributors to physician offices, pharmacies, and hospitals. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was founded in 2003 and is headquartered in Alpharetta, Georgia.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-04 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CGC Canopy Growth Corporation

-2.23 (-6.71%)

USD12.62B N/A N/A
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
APHA Aphria Inc

-1.47 (-8.09%)

USD5.75B 60.80 454.68
TLRY Tilray, Inc

-2.64 (-10.44%)

USD4.34B N/A N/A
CRON Cronos Group Inc

-0.67 (-6.50%)

USD3.71B 37.00 N/A
PCRX Pacira BioSciences, Inc

-2.13 (-3.07%)

USD3.01B 20.83 68.83
SNDL Sundial Growers Inc

-0.14 (-10.77%)

USD2.03B -99,999.99 N/A
ORGO Organogenesis Holdings Inc

-0.83 (-5.38%)

USD1.97B 456.50 145.92
IRWD Ironwood Pharmaceuticals, Inc

+0.02 (+0.20%)

USD1.60B 15.11 11.95

ETFs Containing ALIM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 81.52% 87% B+ 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 81.52% 87% B+ 95% A
Trailing 12 Months  
Capital Gain 14.84% 64% D 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.84% 64% D 41% F
Trailing 5 Years  
Capital Gain -72.40% 24% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -72.40% 24% F 6% F
Average Annual (5 Year Horizon)  
Capital Gain -24.44% 22% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.44% 22% F 5% F
Risk Return Profile  
Volatility (Standard Deviation) 25.70% 88% B+ 57% F
Risk Adjusted Return -95.08% 10% F 3% F
Market Capitalization 0.05B 10% F 10% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1.13 84% B 89% B+
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A N/A N/A
EV/EBITDA 40.74 38% F 24% F
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -1.26% 80% B- 49% F
Return on Assets -0.62% 76% C 44% F
Debt to Equity Ratio -531.56% 90% A- 99% A+
Technical Ratios  
Short Ratio 1.14 61% D- 64% D
Short Percent 2.68% 75% C 55% F
Beta 1.64 25% F 24% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.